Convergence: where pharmaceuticals have been, devices will follow
This article was originally published in Clinica
Regulators are increasingly looking at devices and medicines in a similar way when it comes to public perception of quality, safety and efficacy, says consultant Mark Charny*. Current requirements for pharmaceuticals may predict the future of device regulation and reimbursement device companies need to adapt their strategies for early-stage products to manage this change
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.